4-Oxo-3-(phenylmethoxy)-4H-pyran-2,5-dicarboxylic acid 2,5-dimethyl ester

We are 4-Oxo-3-(phenylmethoxy)-4H-pyran-2,5-dicarboxylic acid 2,5-dimethyl ester CAS:1246616-66-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Oxo-3-(phenylmethoxy)-4H-pyran-2,5-dicarboxylic acid 2,5-dimethyl ester
CAS.NO:1246616-66-9
Synonyms:4-Oxo-3-(phenylmethoxy)-4H-pyran-2,5-dicarboxylic acid 2,5-dimethyl ester
dimethyl 3-(benzyloxy)-4-oxo-4H-pyran-2,5-dicarboxylate
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 534.9±50.0 °C at 760 mmHg
Molecular Formula C16H14O7
Molecular Weight 318.278
Flash Point 238.9±30.2 °C
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.567
 
Specification:
Appearance:White or off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Dolutegravir(CAS:1051375-16-6).

4-Oxo-3-(phenylmethoxy)-4H-pyran-2,5-dicarboxylic acid 2,5-dimethyl ester


Related News: The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon.2,3-dihidrobenzo [b] furan-5-carbaldehído CAS:55745-70-5 The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.6-Chloro-3-methyluracil CAS:4318-56-3 The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.3-Fluoro-4-nitrobenzoic acid Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.

Related Products
Product Name
(2,5-dioxopyrrolidin-1-yl) 2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoate View Details
3-Methacryloxypropylmethyldimethoxysilane View Details
N,O-Dimethylhydroxylamine hydrochloride View Details
4-Bromobenzo[b]thiophene manufacturer (2S,5R)-5-(benzyloxyamino)-piperidine-2-carboxylic acid amide manufacturer Ethyl 3-ethoxypropionate manufacturer 3-(2-Methoxy-5-methylphenyl)-3-phenyl-propanoic Acid manufacturer 1-bromobut-2-yne manufacturer